Cargando…

NF-kB and the CLL microenvironment

Chronic lymphocytic leukemia (CLL) is the most prevalent type of leukemia in the western world. Despite the positive clinical effects of new targeted therapies, CLL still remains an incurable and refractory disease and resistance to treatments are commonly encountered. The Nuclear Factor-Kappa B (NF...

Descripción completa

Detalles Bibliográficos
Autores principales:	O’Donnell, Alice, Pepper, Chris, Mitchell, Simon, Pepper, Andrea
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10098180/ https://www.ncbi.nlm.nih.gov/pubmed/37064123 http://dx.doi.org/10.3389/fonc.2023.1169397

Ejemplares similares

NF-κB fingerprinting reveals heterogeneous NF-κB composition in diffuse large B-cell lymphoma
por: Jayawant, Eleanor, et al.
Publicado: (2023)

LMO1 Plays an Oncogenic Role in Human Glioma Associated With NF-kB Pathway
por: Gao, Lei, et al.
Publicado: (2022)

The Hsp90 inhibitor NVP-AUY922-AG inhibits NF-κB signaling, overcomes microenvironmental cytoprotection and is highly synergistic with fludarabine in primary CLL cells
por: Walsby, Elisabeth, et al.
Publicado: (2012)

hZIP1 Inhibits Progression of Clear Cell Renal Cell Carcinoma by Suppressing NF-kB/HIF-1α Pathway
por: Zhan, Bo, et al.
Publicado: (2021)

Characterization of NF-kB-mediated inhibition of catechol-O-methyltransferase
por: Tchivileva, Inna E, et al.
Publicado: (2009)

Retraction: Combination of Tanshinone IIA and Cisplatin Inhibits Esophageal Squamous Cell Carcinoma by Down-Regulating NF-kB/COX-2/VEGF Pathway
Publicado: (2021)

Knockdown of USP8 inhibits prostate cancer cell growth, proliferation, and metastasis and promotes docetaxel’s activity by suppressing the NF-kB signaling pathway
por: Islam, Md. Tariqul, et al.
Publicado: (2022)

NF-kB Expression in IgA Nephropathy Outcome
por: Silva, G. E. B., et al.
Publicado: (2011)

NF-kB pathway is involved in microscopic colitis pathogenesis
por: Pisani, Laura Francesca, et al.
Publicado: (2022)

IκBα beyond the NF-kB dogma
por: Mulero, Maria Carmen, et al.
Publicado: (2013)

Telomere length predicts for outcome to FCR chemotherapy in CLL
por: Norris, Kevin, et al.
Publicado: (2019)

Telomere fusions associate with coding sequence and copy number alterations in CLL
por: Escudero, Laura, et al.
Publicado: (2019)

Retraction: Corrigendum: Tan IIA Combined With DDP Inhibits Esophageal Squamous Cell Carcinoma via Down-Regulating the NF-kB/COX-2/VEGF Pathway
Publicado: (2021)

NF-kB inhibitor blocks B cell development at two checkpoints
por: Feng, Biao, et al.
Publicado: (2004)

The SUMOylation machinery is dispensable for Tax-induced NF-kB activation
por: Pène, Sabrina, et al.
Publicado: (2014)

Diisononyl phthalate aggravates allergic dermatitis by activation of NF-kB
por: Kang, Jun, et al.
Publicado: (2016)

NF‐kB signaling in cardiomyocytes is inhibited by sevoflurane and promoted by propofol
por: Oda‐Kawashima, Keiko, et al.
Publicado: (2020)

The Pivotal Role of NF-kB in the Pathogenesis and Therapeutics of Alzheimer’s Disease
por: Sun, Emily, et al.
Publicado: (2022)

Coilin as a regulator of NF-kB mediated inflammation in preeclampsia
por: Logan, Madelyn K., et al.
Publicado: (2022)

Activation of NF-kB pathway in Duchenne muscular dystrophy: relation to age
por: MESSINA, S., et al.
Publicado: (2011)

Activation of NF-kB Pathway by Virus Infection Requires Rb Expression
por: Garcia, Maria A., et al.
Publicado: (2009)

COVID-19 and NF-kB: The Hepcidin paradox and the Iron Storm - reply
por: Banchini, Filippo
Publicado: (2020)

Identification of proliferative and non-proliferative subpopulations of leukemic cells in CLL
por: Cuthill, Kirsty M., et al.
Publicado: (2022)

Targeting the Non-Canonical NF-κB Pathway in Chronic Lymphocytic Leukemia and Multiple Myeloma
por: Burley, Thomas A., et al.
Publicado: (2022)

LINC00467 Promotes Tumor Progression via Regulation of the NF-kb Signal Axis in Bladder Cancer
por: Xiao, Jiawei, et al.
Publicado: (2021)

CLL kinetics in the tumor microenvironment
por: Sun, Clare, et al.
Publicado: (2017)

A CD21 low phenotype, with no evidence of autoantibodies to complement proteins, is consistent with a poor prognosis in CLL
por: Nichols, Eva-Maria, et al.
Publicado: (2015)

The Nuclear Factor Kappa B (NF-kB) signaling in cancer development and immune diseases
por: Zinatizadeh, Mohammad Reza, et al.
Publicado: (2020)

Carcinoma Matrix Controls Resistance to Cisplatin through Talin Regulation of NF-kB
por: Eberle, Karen E., et al.
Publicado: (2011)

Predominant role of Tax sumoylation in Tax-induced NF-kB activation in T cells
por: Bonnet, Amandine, et al.
Publicado: (2011)

Partners in death: a role for p73 and NF-kB in promoting apoptosis
por: Vousden, Karen H.
Publicado: (2009)

Reciprocal Regulation of NF-kB (Relish) and Subolesin in the Tick Vector, Ixodes scapularis
por: Naranjo, Victoria, et al.
Publicado: (2013)

PUMA and NF-kB Are Cell Signaling Predictors of Reovirus Oncolysis of Breast Cancer
por: Thirukkumaran, Chandini, et al.
Publicado: (2017)

Vaccine-modified NF-kB and GR Signaling in Cervicovaginal Epithelium Correlates with Protection
por: Shang, L., et al.
Publicado: (2017)

Dysregulation of NF-kB in glandular epithelial cells results in Sjögren’s-like features
por: Wang, Xiaoyan, et al.
Publicado: (2018)

Data on hypoxia-induced VEGF, leptin and NF-kB p65 expression
por: Al-Anazi, Azizah, et al.
Publicado: (2018)

Quercetin reduces the transcriptional activity of NF-kB in stable coronary artery disease()
por: Chekalina, Nataliya, et al.
Publicado: (2018)

HSP70 alleviates spinal cord injury by activating the NF-kB pathway
por: Xu, Bingqiang, et al.
Publicado: (2021)

EV-Mediated Chemoresistance in the Tumor Microenvironment: Is NF-κB a Player?
por: Di Vito Nolfi, Mauro, et al.
Publicado: (2022)

Characterizing Features of Human Circulating B Cells Carrying CLL-Like Stereotyped Immunoglobulin Rearrangements
por: Bagnara, Davide, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_71pjc465jcd89l3uu6g00ottrj